Immunotherapie and Immunology news
A 2026 meta-analysis of 15 RCTs shows MSCs cut acute GvHD incidence by 53% and chronic GvHD by 50%. A biomarker-guided trial identifies which transplant patients benefit most — and a cell-free exosome approach may be next.
Read More »Your body’s stem cell population drops dramatically after 40. Here’s what the science says about why we age — and how regenerative medicine is fighting back.
Read More »A technical review of 3D bioprinting for cartilage repair: thiolated bioinks, scaffold optimization, MSC chondrogenesis, and the path to clinical translation.
Read More »Learn how MSC therapy is offering real hope for liver cirrhosis patients — with data from the latest 2026 clinical trials and real patient outcomes at our Bangkok clinic.
Read More »A technical deep dive into MSC immunomodulation for autoimmune disease: Treg induction, macrophage polarization, and clinical evidence from the SMART-MS trial.
Read More »